Oruka Therapeutics Is A Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative Monoclonal Antibody Therapies For Chronic Skin Diseaseswith A Primary Focus On Psoriasis And Psoriatic Arthritisthe Company Aims To Improve Treatment Standards By Targeting The Underlying Mechanisms Of These Diseasesstriving For Higher Rates Of Complete Skin Clearance And More Convenient Dosing Options Oruka S Lead Productorka 001Is A Half Life Extended Il 23P19 Monoclonal Antibody Currently In Clinical Developmentthe Company Is Also Preparing To Advance Orka 002An Undisclosed Biologic Candidateinto Clinical Trials In 2025With A Strong Emphasis On Antibody Engineeringoruka Seeks To Enhance Therapeutic Performance And Reduce Dosing Frequencyultimately Improving The Quality Of Life For Patients Affected By Autoimmune Skin Conditionsthe Leadership Teamled By Ceo Lawrence Kleinphdhas Successfully Raised Over $475 Million In Funding To Support Their Mission And Extend Their Operational Runway Through 2027
No conferences found for this company.
| Company Name | Arca Biopharma Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
